Literature DB >> 18444798

CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus.

Andrea Kovacs1, Lena Al-Harthi, Shawna Christensen, Wendy Mack, Mardge Cohen, Alan Landay.   

Abstract

Immune activation is a hallmark of human immunodeficiency virus type 1 (HIV-1) infection and impacts innate and adaptive immunity. Individuals coinfected with HIV-1 and hepatitis C virus (HCV) may have increased immune activation early in HIV disease because of a high HCV antigen load in tissues such as the liver. We evaluated T cell markers of activation and maturation in women with or without HIV-1 infection, by HCV antibody and HCV RNA status. We found increased percentages of activated CD8(+) T cells (i.e., CD8(+)HLA-DR(+)38(+) cells and CD8(+)CD28(+)HLA-DR(+) cells) but not of CD4(+) T cells among women who tested positive for HIV-1, HCV antibody, and HCV RNA, compared with HIV-1-positive women who tested negative for HCV antibody. Because CD8(+) T cell activation is related to HIV-1 disease progression, these data may have implications for the medical management of patients coinfected with HIV-1 and HCV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18444798      PMCID: PMC2443164          DOI: 10.1086/587696

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  HIV coinfection impairs CD28-mediated costimulation of hepatitis C virus-specific CD8 cells.

Authors:  Nicole L Yonkers; Benigno Rodriguez; Anthony B Post; R Asaad; Linda Jones; Michael M Lederman; Paul V Lehmann; Donald D Anthony
Journal:  J Infect Dis       Date:  2006-06-30       Impact factor: 5.226

2.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study.

Authors:  G Greub; B Ledergerber; M Battegay; P Grob; L Perrin; H Furrer; P Burgisser; P Erb; K Boggian; J C Piffaretti; B Hirschel; P Janin; P Francioli; M Flepp; A Telenti
Journal:  Lancet       Date:  2000-11-25       Impact factor: 79.321

3.  Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive/HIV-infected women.

Authors:  Tomasz Laskus; Eva A Operskalski; Marek Radkowski; Jeffrey Wilkinson; Wendy J Mack; Marina deGiacomo; Lena Al-Harthi; Zhi Chen; Jiaao Xu; Andrea Kovacs
Journal:  J Infect Dis       Date:  2006-11-27       Impact factor: 5.226

4.  Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study.

Authors:  Nina Weis; Bjarne O Lindhardt; Gitte Kronborg; Ann-Brit E Hansen; Alex L Laursen; Peer B Christensen; Henrik Nielsen; Axel Moller; Henrik T Sorensen; Niels Obel
Journal:  Clin Infect Dis       Date:  2006-04-12       Impact factor: 9.079

5.  Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV/HIV-coinfected women: role of HCV on expression of primed/memory T cells.

Authors:  Lena Al-Harthi; John Voris; Wenbo Du; David Wright; Marek Nowicki; Toni Frederick; Alan Landay; Andrea Kovacs
Journal:  J Infect Dis       Date:  2006-03-17       Impact factor: 5.226

6.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

Authors:  Jürgen K Rockstroh; Amanda Mocroft; Vincent Soriano; Cristina Tural; Marcello H Losso; Andrzej Horban; Ole Kirk; Andrew Phillips; Bruno Ledergerber; Jens Lundgren
Journal:  J Infect Dis       Date:  2005-08-11       Impact factor: 5.226

7.  Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T cells.

Authors:  Michaela Lucas; Ana L Vargas-Cuero; Georg M Lauer; Eleanor Barnes; Christian B Willberg; Nasser Semmo; Bruce D Walker; Rodney Phillips; Paul Klenerman
Journal:  J Immunol       Date:  2004-02-01       Impact factor: 5.422

8.  Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study.

Authors:  Katie B Anderson; Jodie L Guest; David Rimland
Journal:  Clin Infect Dis       Date:  2004-10-25       Impact factor: 9.079

9.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.

Authors:  Victor Appay; P Rod Dunbar; Margaret Callan; Paul Klenerman; Geraldine M A Gillespie; Laura Papagno; Graham S Ogg; Abigail King; Franziska Lechner; Celsa A Spina; Susan Little; Diane V Havlir; Douglas D Richman; Norbert Gruener; Gerd Pape; Anele Waters; Philippa Easterbrook; Mariolina Salio; Vincenzo Cerundolo; Andrew J McMichael; Sarah L Rowland-Jones
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

Review 10.  Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection.

Authors:  Laura Papagno; Celsa A Spina; Arnaud Marchant; Mariolina Salio; Nathalie Rufer; Susan Little; Tao Dong; Gillian Chesney; Anele Waters; Philippa Easterbrook; P Rod Dunbar; Dawn Shepherd; Vincenzo Cerundolo; Vincent Emery; Paul Griffiths; Christopher Conlon; Andrew J McMichael; Douglas D Richman; Sarah L Rowland-Jones; Victor Appay
Journal:  PLoS Biol       Date:  2004-02-17       Impact factor: 8.029

View more
  50 in total

Review 1.  HIV infection, inflammation, immunosenescence, and aging.

Authors:  Steven G Deeks
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 2.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

Review 3.  Inflammation, immune activation, and cardiovascular disease in HIV.

Authors:  Eric Nou; Janet Lo; Steven K Grinspoon
Journal:  AIDS       Date:  2016-06-19       Impact factor: 4.177

4.  Differences in Response to Antiretroviral Therapy by Sex and Hepatitis C Infection Status.

Authors:  Julia L Marcus; Wendy A Leyden; Chun R Chao; Lanfang Xu; Charles P Quesenberry; Phyllis C Tien; Daniel B Klein; William J Towner; Michael A Horberg; Michael J Silverberg
Journal:  AIDS Patient Care STDS       Date:  2015-05-18       Impact factor: 5.078

5.  CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies.

Authors:  Katherine Tassiopoulos; Alan Landay; Ann C Collier; Elizabeth Connick; Steven G Deeks; Peter Hunt; Dorothy E Lewis; Cara Wilson; Ronald Bosch
Journal:  J Infect Dis       Date:  2012-03-23       Impact factor: 5.226

Review 6.  HIV and Bone Complications: Understudied Populations and New Management Strategies.

Authors:  Michael T Yin; Todd T Brown
Journal:  Curr HIV/AIDS Rep       Date:  2016-12       Impact factor: 5.071

7.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

Review 8.  Coinfecting viruses as determinants of HIV disease.

Authors:  Andrea Lisco; Christophe Vanpouille; Leonid Margolis
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

9.  PD-1 expression on peripheral CD8+ TEM/TEMRA subsets closely correlated with HCV viral load in chronic hepatitis C patients.

Authors:  Tao Shen; Jiajia Zheng; Chunhui Xu; Jia Liu; Weidong Zhang; Fengmin Lu; Hui Zhuang
Journal:  Virol J       Date:  2010-11-12       Impact factor: 4.099

10.  High-risk oncogenic HPV genotype infection associates with increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected women.

Authors:  Emmanouil Papasavvas; Lea F Surrey; Deborah K Glencross; Livio Azzoni; Jocelin Joseph; Tanvier Omar; Michael D Feldman; Anna-Lise Williamson; Maureen Siminya; Avril Swarts; Xiangfan Yin; Qin Liu; Cynthia Firnhaber; Luis J Montaner
Journal:  Oncoimmunology       Date:  2016-01-19       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.